 | This article has multiple issues. Please helpimprove it or discuss these issues on thetalk page.(Learn how and when to remove these messages) (Learn how and when to remove this message)
|
 | |
 Headquarters atElectronic City,Bangalore | |
| Company type | Public |
|---|---|
| BSE: 532523 NSE: BIOCON | |
| ISIN | INE376G01013 |
| Industry | |
| Founded | 1978 (47 years ago) (1978) |
| Founder | Kiran Mazumdar-Shaw |
| Headquarters | , India |
Key people |
|
| Products |
|
| Revenue |  ₹16,470 crore (US$1.9 billion) (2025) |
| ₹4,374 crore (US$520 million) (2025) | |
 ₹1,013 crore (US$120 million) (2025) | |
| Total assets | ₹58,797 crore (US$7.0 billion) (2025) |
| Total equity | ₹27,712 crore (US$3.3 billion) (2025) |
Number of employees | 16,545(March 2023)[1] |
| Subsidiaries |
|
| Website | www |
| Footnotes / references Financials as of 31 March 2025[update].[2][3] | |
Biocon Limited is an Indianbiopharmaceutical company based inBengaluru, with U.S.headquarters inBridgewater,New Jersey. The company was founded byKiran Mazumdar-Shaw in 1978.[4] The company manufacturesgenericactive pharmaceutical ingredients (APIs) that are sold in approximately 120 countries,[5] including the United States and Europe.[4] It also manufactures novel biologics as well asbiosimilar insulins andantibodies, which are sold in India as branded formulations. Biocon's biosimilar products are also sold in both bulk and formulation forms in several emerging markets.[6]
Biocon's formulations for the Indian market includemetabolics,oncology,immunotherapy, andnephrology products. Some of Biocon's key brands in India include INSUGEN (rh-insulin), BASALOG (Glargine), BIOMAb EGFR (Nimotuzumab), BLISTO (Glimepiride +Metformin), CANMAb (Trastuzumab), Evertor (Everolimus), TACROGRAF (Tacrolimus), ALZUMAb (Itolizumab) and KRABEVA (Bevacizumab).[4]
Syngene International Limited (Syngene) is a publicly listed subsidiary of Biocon, operating in thecontract research and development organization.[4]
 | This sectionis inlist format but may read better asprose. You can help byconverting this section, if appropriate.Editing help is available.(July 2025) |
Biocon was founded in 1978 with US$10,000 as the initial capital by aKiran Mazumdar who was born toGujarati parents inBangaluru.[7][8]
In 1979, Biocon became the first Indian company to manufacture and exportenzymes to the US and Europe.[9]
In 1989,Unilever acquired Biocon Biochemicals Ltd. in Ireland and merged it with its subsidiary Quest International. Biocon received US funding for proprietary technologies.[10]
In 1994, Biocon established Syngene International as a custom research company.[10]
During 1998, Unilever agreed to sell its shareholding in Biocon to the Indian promoters. Biocon became an independent entity.[11]
In 2001, Biocon became the first Indian company to be approved by theUSFDA for the manufacture oflovastatin; PlaFractor was granted a US 2001 and worldwide patent.[12]
In 2003, Biocon became the first company worldwide to develop human insulin on apichia expression system.[13]
In 2006, BIOMAb EGFR, the first indigenously developed humanised monoclonal antibody for head-and-neck cancer, was launched, andAPJ Abdul Kalam inaugurated India's largest biotech-hub, Biocon Park.[14]
In 2008, Biocon acquired a 70% stake in German pharmaceutical company AxiCorp GmbH.[15]
During 2009, a Syngene-Bristol Myers Squibb research facility was established in Bengaluru.[16]
Later in 2009,Mylan announced a strategic collaboration with Biocon to enter the global generic biologics market.[17]
In 2010, Biocon expanded toMalaysia, with a biopharmaceutical manufacturing and R&D facility established inIskandar,Johor.[18]
In 2012,Abbott announced a collaboration with Syngene to open the first nutrition R&D center in India.[19]
During 2013, Biocon launched the biologic drug ALZUMAb to treatpsoriasis.[20]
During 2014, Biocon launched the first biosimilar drug, CANMAb, to treatbreast cancer.[21]
In 2015, Biocon launched ahepatitis-C drug in India under the brand name CIMIVIR-L.[22]
In 2016, Biocon became the first Indian company to launch abiosimilarinsulin glargine pen in Japan.[23]
During 2016, Syngene set up anAmgen R&D center in Bangalore.[24]
In 2017, Biocon's Insugen became the first locally manufactured biosimilar product to be approved for sale by the Malaysian drug regulator.[25]
In 2017, USFDA approvedMylan-Biocon's biosimilar for the cancer drugHerceptin.[26]
During 2018, Biocon and Mylan received the European Commission's approval to market the biosimilar insulin glargine.[27]
During 2021, Biocon Biologics andSerum Institute of India formed a joint agreement to commercialise vaccines, biological drugs, and antibody therapies together.[28] Another aspect of the deal involved Bicocon selling 15% of its biologics subsidiary to theSerum Institute of India, in return for Biocon gaining access to 100 million annual doses of vaccines for a 15-year period.[28]
During 2022, Biocon Biologics bought thebiosimilar assets ofViatris for $3.34 billion.[29]
Biocon's CMDKiran Mazumdar-Shaw joined Biocon in 1978.[30][31][32] Her efforts in biotechnology have drawn global recognition both for the industry in India and for Biocon. She was called India's "biotech queen" byThe Economist[33] and India's "mother of invention" byThe New York Times.[34] She was named amongTime magazine's 2010 100 most influential people in the world, not only due to her contribution to the biotech industry, but also because she gives back to the community.[35] Shaw has been featured on theForbes list of "The World's 100 Most Powerful Women"[36] and in theFinancial Times "Top 50 Women in Business" list.[37]
Shaw is the recipient of several awards including theNikkei Asia Prize, 2009 for Regional Growth,[38] Express Pharmaceutical Leadership Summit Award 2009 for Dynamic Entrepreneur,The Economic Times 'Businesswoman of the Year', the 'Veuve Clicquot Initiative For Economic Development For Asia,Ernst & Young's Entrepreneur of the Year Award for Life Sciences & Healthcare, 'Technology Pioneer' recognition by World Economic Forum and the Indian Chamber of Commerce Lifetime Achievement Award. She has received two Indian national awards, thePadma Shri (1989) andPadma Bhushan (2005), for her pioneering efforts in industrial biotechnology.[30]
Christiane Hamacher was appointed as the CEO of Biocon Biologic India Limited, with her term starting in March 2019.[39]
On 3 December 2019, Siddharth Mittal took over from Arun Chandavarkar, who retired asCEO and joint managing director of Biocon.[40]
In 2021, Hamacher resigned from her position, following differences with Kiran Mazumdar-Shaw.[41]
Biocon Biologics is Biocon's biosimilar subsidiary. In 2021, Biocon and Viatris received approval to launchSemglee, an insulin glargine-yfgn injection, the first interchangble biosimilar fordiabetes in the United States.[42] In 2021, Biocon sold 15% of Biocon Biologics toSerum Institute of India for a valuation of $4.9 billion, for which Biocon will receive access to 100 million doses of vaccines per annum for 15 years.[43] These vaccines will mainly be supplied from Serum Institute's upcoming vaccine facility in Pune, and Biocon will also have the commercialization rights of Serum Institute's vaccine portfolio, which includes the COVID-19 vaccine, for the international markets.[43] In May 2022, Viatris sold its biosimilars division to Biocon Biologics for a price of US$3.335 billion.[44]
Established in 1993, Syngene International Limited is acontract research and development organization (CDMO). In the CDMO space, Syngene primarily focuses on research innovation and manufacturing services for their clients.[45] The company has four divisions:drug discovery services, dedicated research centres, development devices and manufacturing.[45] Syngene works with eight of the top 10 global pharma companies and, Syngene's clients include Amgen,Zoetis,GlaxoSmithKline and Bristol Myers Squibb.[46] Syngene has been expanding its operations. Since 2020, the company has opened an R&D centre in Hyderabad, is building an API manufacturing facility inMangalore, which was scheduled to be commissioned in 2022, and has expanded their R&D facility in Bangalore.[47] Syngene also provides biologics CDMO services.[48] In July 2022, Syngene signed a 10-year agreement with Zoetis to manufacture the drug substance for Librela (bedinvetmab), afirst-in-classmonoclonal antibody used for treatingosteoarthritis in dogs.[49] SynVent is Syngene's drug discovery and development platform for bothsmall andlarge molecules.[50] In September 2022, Biocon divested 5.4% of its shares in Syngene International.[51]
Clinigene International Limited is a subsidiary of Syngene offering international pharmaceutical majors Phase I-IV clinical trials and studies for novel/generic molecules.[30]
Biocon established Biocon Biopharmaceuticals Pvt. Ltd. (BBPL) in 2003 as a joint venture with the Cuban institute CIMAB to develop and market a range of MAbs and cancer vaccines.[30]
In 2008, Biocon acquired a majority stake of 70% in AxiCorp GmbH, a German pharmaceutical marketing company.[52]
Incorporated in January 2008, NeoBiocon FZ LLC is a research and marketing pharmaceutical company based inAbu Dhabi.[53]
Biofusion Therapeutics Limited was incorporated in March 2021. It is 100% owned by Biocon.[54]
In 2009, Biocon andAmylin Pharmaceuticals of the United States entered into an agreement to develop, commercialise and manufacture a novel peptide therapeutic for the potential treatment of diabetes. Amylin provides expertise in peptide hormone development, particularly in the area of phybrid technology and metabolic disease therapeutics. Biocon will utilise its expertise in recombinant microbial expression and experience in preclinical and clinical development of diabetes products to manufacture the compound.[30]
In 2008, Biocon and IATRICa of the United States announced a strategic partnership to co-develop immunoconjugates for targeted immunotherapy of cancers and infectious diseases. The companies are co-developing candidate products based upon IATRICa's technology platform and Biocon's expertise in drug development, biologics manufacturing, and clinical research. The goal of this collaboration is to develop a therapeutic vaccine where the T cell-mediated immunity is enhanced and maintained against a tumor that otherwise evades immune responses. Methods of developing, characterising and scaling up of conjugated monoclonal antibody production are being currently studied.[30]
In 2009, Biocon signed a collaboration agreement withViatris to develop and commercialize generic biologics. Viatris and Biocon will share development, capital, and other costs to bring products to market. Viatris will have exclusive commercialisation rights in the USA, Canada, Japan, Australia, New Zealand, EU, and European Free Trade Association countries through a profit-sharing arrangement with Biocon.[30]
Biocon andOptimer Pharmaceuticals, a biopharmaceutical company focused on the treatment of serious infections such asClostridioides difficile infection (CDI), have entered into a long-term supply agreement for the commercial manufacturing of the active pharmaceutical ingredient, fidaxomicin.[4][30]
Biocon is also developing fully human antibodies BVX 10 and BVX-20 with a US antibody technology partner, Vaccinex. The partnership was initiated in 2004. BVX 10 targets TNF (Tumor Necrosis Factor) which is expressed at high levels in patients with rheumatoid arthritis. Biocon's strategic partnership with Vaccinex allows access to their proprietary human antibody platform technology, thereby providing a strong IP protection to Biocon's antibody pipeline.[4][30]
In 2007, Biocon andAbraxis BioScience, Inc. entered into an agreement that helped Biocon out-license the rights to develop and market a biosimilar version ofGCSF (Granulocyte Colony-Stimulating Factor) to North American and European markets.[30]
In January 2018,Sandoz (aNovartis division) announced a global partnership with Biocon to develop, manufacture, and commercialize multiple biosimilars in immunology and oncology for patients worldwide.[55]
Biocon's manufacturing facilities are located at two sites inBangalore.[30]
Biocon'sR&D focuses on the entire drug development pathway – from process development to non-clinical and clinical research.[30]
Biocon offers 36 brands of products across the four therapeutic divisions ofdiabetology,nephrology,oncology, andcardiology.[4]
| History | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Geography |
| ||||||||||||
| Civil administration |
| ||||||||||||
| Buildings | |||||||||||||
| Transport | |||||||||||||
| Roads | |||||||||||||
| Places of worship | |||||||||||||
| Culture |
| ||||||||||||
| Groups | |||||||||||||
| Parks | |||||||||||||
| |||||||||||||
| |||||||||||||
